1. Home
  2. SRRK

SRRK

Scholar Rock Holding Corporation

Logo Scholar Rock Holding Corporation

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

as 04-19-2024 2:30pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGFβ1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.

Founded: 2012 Country:
United States
United States
Employees: N/A City: CAMBRIDGE
Market Cap: 1.1B IPO Year: 2018
Target Price: $25.33 AVG Volume (30 days): 793.2K
Analyst Decision: Strong Buy Number of Analysts: 6
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.99 EPS Growth: N/A
52 Week Low/High: $5.56 - $21.17 Next Earning Date: 05-07-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: